Connect your AI

Veradermics MANE Cumulative Cost Basis

Cumulative Cost Basis at other companies

CitigroupC

-$800M-500%

Ares CapitalARCC

$29.3B—

Ally FinancialALLY

$94M+23.7%

Ares CapitalARCC

$29.2B+10.2%

AGNC Investment Corp.AGNC

$8.53B+151%

Corebridge FinancialCRBG

——

Other financials

Income statement

Operating income-$29.9M-131%

Net income-$27.2M-120%

EPS (diluted)-$1.32+93.3%

Balance sheet

Cash & equivalents$168.4M+419%

Total debt$4.0K—

Total equity$390.6M+744%

Total assets$397.4M—

Cash flow

Operating cash flow-$21.2M-59.0%

CapEx--100%

Free cash flow-$21.2M-58.7%

Valuation

Market cap$3.92B—

Returns & leverage

Return on equity-28.7%—

Current ratio59.1×—

Where this comes from

Reported directly by Veradermics in its filing.

Tagged under the XBRL concept us-gaap:AvailableForSaleDebtSecuritiesAmortizedCostBasis.

The official record: Veradermics ’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Veradermics 's cumulative cost basis.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Harbor at dusk

Questions, answered.

What is Veradermics 's cumulative cost basis?: Veradermics (MANE) reported cumulative cost basis of $390.13M in Q1 2026.